Vorasidenib

CAS : 1644545-52-7

Ref. 3D-UQC54552

Informations sur le produit

• Nom: Vorasidenib
• Synonymes: AG-881
• Marque: Biosynth
• Description: Vorasidenib is a drug that has been approved for the treatment of adults with newly diagnosed glioblastoma. It is currently being investigated in preoperative settings, to see if it can reduce or eliminate the need for radiation therapy. Vorasidenib is an anti-angiogenic drug that blocks both vascular endothelial growth factor and platelet-derived growth factor receptors, which are key components of tumor angiogenesis. The drug has been shown to prolong survival in patients with malignant brain tumors and has few serious side effects. A multicenter phase II study showed a response rate of about 20% in patients with newly diagnosed gliomas who were given vorasidenib. Pharmacokinetic studies have demonstrated that vorasidenib crosses the blood-brain barrier and penetrates into the tumor cells at levels higher than other drugs used to treat gliomas.

Propriétés chimiques

• Masse moléculaire: 414.74 g/mol
• Formule: C₁₄H₁₃ClF₆N₆
• Degré de pureté: Min. 95%